Mabpharm Limited

SEHK:2181 Stock Report

Market Cap: HK$1.1b

Mabpharm Past Earnings Performance

Past criteria checks 0/6

Mabpharm's earnings have been declining at an average annual rate of -2%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 39.8% per year.

Key information

-2.0%

Earnings growth rate

0.6%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate39.8%
Return on equity-179.6%
Net Margin-136.5%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Investors Don't See Light At End Of Mabpharm Limited's (HKG:2181) Tunnel

Dec 22
Investors Don't See Light At End Of Mabpharm Limited's (HKG:2181) Tunnel

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Jun 14
Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Jan 24
More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Oct 20
Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Jan 18
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Oct 07
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Apr 28
Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

Mar 03
Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Jan 27
We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

Dec 09
Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

Revenue & Expenses Breakdown

How Mabpharm makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SEHK:2181 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24152-207210120
31 Mar 24119-208182122
31 Dec 2387-209154123
30 Sep 2379-202142126
30 Jun 2371-194131129
31 Mar 2364-202125139
31 Dec 2256-211119148
30 Sep 2243-237119163
30 Jun 2230-263119178
31 Mar 2257-278110221
31 Dec 2183-292100264
30 Sep 2182-28489243
30 Jun 2181-27679223
31 Mar 2141-23072172
31 Dec 200-18566120
30 Sep 205-16366128
30 Jun 2011-14166136
31 Mar 2012-17264135
31 Dec 1914-20363134
30 Sep 1916-20860128
30 Jun 1917-21257121
31 Mar 1921-16950105
31 Dec 1824-1254289
31 Dec 175-312522

Quality Earnings: 2181 is currently unprofitable.

Growing Profit Margin: 2181 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 2181 is unprofitable, and losses have increased over the past 5 years at a rate of 2% per year.

Accelerating Growth: Unable to compare 2181's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2181 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.4%).

Return on Equity

High ROE: 2181 has a negative Return on Equity (-179.64%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 05:25
End of Day Share Price 2025/01/28 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mabpharm Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yue-Kwong LuiJefferies LLC